American Well (AMWL) 10-Q 12 Aug 21 2021 Q2 Quarterly report Financial data

Cover Page

Cover Page - shares	6 Months Ended
	Jun. 30, 2021	Jul. 31, 2021
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q2
Trading Symbol	AMWL
Entity Registrant Name	American Well Corporation
Entity Central Index Key	0001393584
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Document Quarterly Report	true
Document Transition Report	false
Security Exchange Name	NYSE
Title of 12(b) Security	Class A common stock,par value of $0.01 per share
Entity File Number	001-39515
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	20-5009396
Entity Address, Address Line One	75 State Street
Entity Address, Address Line Two	26th Floor
Entity Address, City or Town	Boston
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02109
City Area Code	617
Local Phone Number	204-3500
Common Class A [Member]
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		210,681,731
Common Class B [Member]
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		26,650,761
Common Class C [Member]
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		5,555,555

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 975,187	$ 941,616
Investments		99,963
Restricted cash	795	1,095
Accounts receivable ($650 and $12,053, from related parties and net of allowances of $1,039 and $1,556, respectively)	35,544	45,296
Inventories	8,929	9,128
Deferred contract acquisition costs	2,450	2,134
Prepaid expenses and other current assets	13,491	14,055
Total current assets	1,036,396	1,113,287
Property and equipment, net	2,985	3,836
Goodwill	193,877	193,877
Intangible assets, net	51,672	55,528
Operating lease right-of-use asset	3,486	6,609
Deferred contract acquisition costs, net of current portion	898	1,327
Other assets	1,246	1,430
Investment in minority owned joint venture	1,759	752
Total assets	1,292,319	1,376,646
Current liabilities:
Accounts payable	5,173	5,797
Accrued expenses and other current liabilities	24,864	42,135
Operating lease liability, current	3,471	6,357
Deferred revenue ($2,238 and $14,421 from related parties, respectively)	57,836	66,693
Total current liabilities	91,344	120,982
Other long-term liabilities	26	64
Operating lease liability, net of current portion	776	1,296
Deferred revenue, net of current portion ($29 and $486 from related parties, respectively)	7,530	8,107
Total liabilities	99,676	130,449
Commitments and contingencies (Note 11)
Stockholders’ deficit:
Preferred stock, $0.01 par value; 100,000,000 shares authorized, no shares issued or outstanding as of June 30, 2021 and as of December 31, 2020
Common stock, $0.01 par value; 1,000,000,000 Class A shares authorized, 209,875,389 and 201,488,097 shares issued, and 209,875,389 and 200,751,168 shares outstanding, respectively; 100,000,000 Class B shares authorized, 26,687,959 and 30,427,128 shares issued, and 26,687,959 and 29,297,382 shares outstanding, respectively; 200,000,000 Class C shares authorized 5,555,555 issued and outstanding as of June 30, 2021 and December 31, 2020	2,422	2,357
Treasury stock, no shares and 1,866,675 shares as of June 30, 2021 and December 31, 2020, respectively		(37,568)
Additional paid-in capital	1,877,497	1,841,405
Accumulated other comprehensive income	140	297
Accumulated deficit	(708,587)	(582,359)
Total American Well Corporation stockholders’ equity	1,171,472	1,224,132
Non-controlling interest	21,171	22,065
Total stockholders’ equity	1,192,643	1,246,197
Total liabilities, preferred stock and stockholders’ equity	$ 1,292,319	$ 1,376,646

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Accounts receivable from related parties	$ 650	$ 12,053
Accounts receivable net of allowances	1,039	1,556
Deferred revenue from related parties current	2,238	14,421
Deferred revenue from related parties non current	$ 29	$ 486
Preferred Stock, Par Value	$ 0.01	$ 0.01
Preferred Stock, Shares Authorized	100,000,000	100,000,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Common Stock, Shares Authorized	1,300,000,000
Common Stock, Shares, Issued	242,118,903
Common Stock, Shares, Outstanding	242,118,903
Treasury Stock, Shares	0	1,866,675
Common Class A [Member]
Common Stock, Par Value	$ 0.01	$ 0.01
Common Stock, Shares Authorized	1,000,000,000	1,000,000,000
Common Stock, Shares, Issued	209,875,389	201,488,097
Common Stock, Shares, Outstanding	209,875,389	200,751,168
Common Class B [Member]
Common Stock, Par Value	$ 0.01	$ 0.01
Common Stock, Shares Authorized	100,000,000	100,000,000
Common Stock, Shares, Issued	26,687,959	30,427,128
Common Stock, Shares, Outstanding	26,687,959	29,297,382
Common Class C [Member]
Common Stock, Par Value	$ 0.01	$ 0.01
Common Stock, Shares Authorized	200,000,000	200,000,000
Common Stock, Shares, Issued	5,555,555	5,555,555
Common Stock, Shares, Outstanding	5,555,555	5,555,555

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations And Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Revenue
($1,462, $15,912, $3,089 and $29,160 from related parties, respectively)	$ 60,217	$ 68,568	$ 117,816	$ 122,282
Costs and operating expenses:
Costs of revenue, excluding depreciation and amortization of intangible assets	33,889	43,826	69,594	76,853
Research and development	22,378	17,637	45,418	32,573
Sales and marketing	14,789	12,346	28,521	26,220
General and administrative	24,212	80,082	45,566	95,424
Depreciation and amortization expense	2,484	2,509	4,990	4,795
Total costs and operating expenses	97,752	156,400	194,089	235,865
Loss from operations	(37,535)	(87,832)	(76,273)	(113,583)
Interest income and other income (expense), net	224	308	285	1,155
Loss before expense from income taxes and loss from equity method investment	(37,311)	(87,524)	(75,988)	(112,428)
Expense from income taxes	(103)	(252)	(412)	(252)
Loss from equity method investment	(722)	(444)	(1,541)	(764)
Net loss	(38,136)	(88,220)	(77,941)	(113,444)
Net loss attributable to non-controlling interest	(277)	(1,562)	(894)	(2,405)
Net loss attributable to American Well Corporation	$ (37,859)	$ (86,658)	$ (77,047)	$ (111,039)
Net loss per share attributable to common stockholders, basic and diluted	$ (0.15)	$ (1.99)	$ (0.31)	$ (2.66)
Weighted-average common shares outstanding, basic and diluted	249,366,652	43,484,313	246,471,733	41,793,108
Net loss	$ (38,136)	$ (88,220)	$ (77,941)	$ (113,444)
Other comprehensive income (loss), net of tax:
Unrealized gain on available-for-sale investments	(119)	(323)	(85)	(280)
Foreign currency translation	(20)	349	(72)	178
Comprehensive loss	(38,275)	(88,194)	(78,098)	(113,546)
Less: Comprehensive loss attributable to non-controlling interest	(277)	(1,562)	(894)	(2,405)
Comprehensive loss attributable to American Well Corporation	$ (37,998)	$ (86,632)	$ (77,204)	$ (111,141)

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Operations And Comprehensive Loss (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Income Statement [Abstract]
Revenue from Related Parties	$ 1,462	$ 15,912	$ 3,089	$ 29,160

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Total	Convertible Preferred Stock [Member]	Common Stock [Member]	Treasury Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Accumulated Equity (Deficit) [Member]	American Well Corporation Stockholder Equity (Deficit) [Member]	Noncontrolling Interest [Member]
Beginning balance at Dec. 31, 2019		$ 655,799	$ 423	$ (158)	$ 50,289	$ 250	$ (357,927)	$ (307,123)	$ 26,259
Beginning balance (in shares) at Dec. 31, 2019		14,012,935	42,302,845
Beginning balance at Dec. 31, 2019	$ (280,864)
Issuance of Series C convertible preferred stock, net of issuance costs		$ 12,489
Issuance of Series C convertible preferred stock, net of issuance costs,Shares		170,000
Exercise of common stock options	2				2			2
Exercise of common stock options, Shares			7,392
Vesting of restricted stock units			$ 1		(1)
Vesting of restricted stock units ,Shares			146,969
Retirement of treasury stock purchased in 2020				158	(158)
Stock-based compensation expense	4,458				4,458			4,458
Currency translation adjustment	(171)					(171)		(171)
Unrealized gain on available-for-sale investments	43					43		43
Net loss	(25,224)						(24,381)	(24,381)	(843)
Ending balance at Mar. 31, 2020		$ 668,288	$ 424		54,590	122	(382,308)	(327,172)	25,416
Ending balance, Shares at Mar. 31, 2020		14,182,935	42,457,206
Ending balance at Mar. 31, 2020	(301,756)
Beginning balance at Dec. 31, 2019		$ 655,799	$ 423	(158)	50,289	250	(357,927)	(307,123)	26,259
Beginning balance (in shares) at Dec. 31, 2019		14,012,935	42,302,845
Beginning balance at Dec. 31, 2019	(280,864)
Currency translation adjustment	178
Unrealized gain on available-for-sale investments	(280)
Net loss	(113,444)
Ending balance at Jun. 30, 2020	(320,145)	$ 801,813	$ 434	(163)	124,548	148	(468,966)	(343,999)	23,854
Ending balance, Shares at Jun. 30, 2020		15,525,685	43,368,541
Beginning balance at Mar. 31, 2020		$ 668,288	$ 424		54,590	122	(382,308)	(327,172)	25,416
Beginning balance (in shares) at Mar. 31, 2020		14,182,935	42,457,206
Beginning balance at Mar. 31, 2020	(301,756)
Issuance of Series C convertible preferred stock, net of issuance costs		$ 133,525
Issuance of Series C convertible preferred stock, net of issuance costs,Shares		1,342,750
Treasury stock	(163)			(163)				(163)
Treasury stock, Shares			(61,600)
Exercise of common stock options	2,330		$ 8		2,322			2,330
Exercise of common stock options, Shares			768,106
Vesting of restricted stock units			$ 2		(2)
Vesting of restricted stock units ,Shares			204,829
Stock-based compensation expense	67,638				67,638			67,638
Currency translation adjustment	349					349		349
Unrealized gain on available-for-sale investments	(323)					(323)		(323)
Net loss	(88,220)						(86,658)	(86,658)	(1,562)
Ending balance at Jun. 30, 2020	(320,145)	$ 801,813	$ 434	(163)	124,548	148	(468,966)	(343,999)	23,854
Ending balance, Shares at Jun. 30, 2020		15,525,685	43,368,541
Beginning balance at Dec. 31, 2020	1,224,132		$ 2,357	(37,568)	1,841,405	297	(582,359)	1,224,132	22,065
Beginning balance (in shares) at Dec. 31, 2020			235,604,105
Beginning balance at Dec. 31, 2020	1,246,197
Exercise of common stock options	10,130		$ 34		10,096			10,130
Exercise of common stock options, Shares			3,474,375
Vesting of restricted stock units			$ 9		(9)
Vesting of restricted stock units ,Shares			853,842
Retirement of treasury stock purchased in 2020				37,568	(15)		(37,553)
Shares withheld related to net share settlement and retired treasury stock in 2021	(9,771)		$ (4)		4		(9,771)	(9,771)
Shares withheld related to net share settlement and retired treasury stock, Shares			(402,060)
Stock-based compensation expense	8,642				8,642			8,642
Currency translation adjustment	(52)					(52)		(52)
Unrealized gain on available-for-sale investments	34					34		34
Net loss	(39,805)						(39,188)	(39,188)	(617)
Ending balance at Mar. 31, 2021			$ 2,396		1,860,123	279	(668,871)	1,193,927	21,448
Ending balance, Shares at Mar. 31, 2021			239,530,262
Ending balance at Mar. 31, 2021	1,215,375
Beginning balance at Dec. 31, 2020	1,224,132		$ 2,357	$ (37,568)	1,841,405	297	(582,359)	1,224,132	22,065
Beginning balance (in shares) at Dec. 31, 2020			235,604,105
Beginning balance at Dec. 31, 2020	1,246,197
Currency translation adjustment	(72)
Unrealized gain on available-for-sale investments	(85)
Net loss	(77,941)
Ending balance at Jun. 30, 2021	1,171,472		$ 2,422		1,877,497	140	(708,587)	1,171,472	21,171
Ending balance, Shares at Jun. 30, 2021			242,118,903
Ending balance at Jun. 30, 2021	1,192,643
Beginning balance at Mar. 31, 2021			$ 2,396		1,860,123	279	(668,871)	1,193,927	21,448
Beginning balance (in shares) at Mar. 31, 2021			239,530,262
Beginning balance at Mar. 31, 2021	1,215,375
Exercise of common stock options	6,674		$ 18		6,656			6,674
Exercise of common stock options, Shares			1,812,491
Vesting of restricted stock units			$ 9		(9)
Vesting of restricted stock units ,Shares			844,900
Shares withheld related to net share settlement and retired treasury stock in 2021	(1,857)		$ (1)		1		(1,857)	(1,857)
Shares withheld related to net share settlement and retired treasury stock, Shares			(68,750)
Stock-based compensation expense	10,726				10,726			10,726
Currency translation adjustment	(20)					(20)		(20)
Unrealized gain on available-for-sale investments	(119)					(119)		(119)
Net loss	(38,136)						(37,859)	(37,859)	(277)
Ending balance at Jun. 30, 2021	1,171,472		$ 2,422		$ 1,877,497	$ 140	$ (708,587)	$ 1,171,472	$ 21,171
Ending balance, Shares at Jun. 30, 2021			242,118,903
Ending balance at Jun. 30, 2021	$ 1,192,643

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2020	Mar. 31, 2020
Series C Preferred Stock [Member]
Convertible preferred stock, issuance costs	$ 750	$ 261

Condensed Consolidated Statem_5

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended				6 Months Ended		12 Months Ended
	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Cash flows from operating activities:
Net loss	$ (38,136)	$ (39,805)	$ (88,220)	$ (25,224)	$ (77,941)	$ (113,444)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense					4,990	4,795
Provisions for doubtful accounts					(57)	640	$ 1,646
Amortization of deferred contract acquisition costs					731	730
Amortization of deferred contract fulfillment costs					351	339
Stock-based compensation expense					19,368	72,096
Loss on equity method investment	722		444		1,541	764
Changes in operating assets and liabilities, net of acquisition:
Accounts receivable					9,809	(8,708)
Inventories					199	(2,107)
Deferred contract acquisition costs					(618)	(1,506)
Prepaid expenses and other current assets					284	(3,004)
Other assets					184	229
Accounts payable					(624)	(2,494)
Accrued expenses and other current liabilities					(16,063)	(687)
Other long-term liabilities					(38)	(195)
Deferred revenue					(9,506)	(5,270)
Net cash used in operating activities					(67,390)	(57,822)
Cash flows from investing activities:
Purchases of property and equipment					(283)	(2,304)
Investment in less than majority owned joint venture					(2,548)	(2,940)
Purchases of investments						(29,777)
Proceeds from sales and maturities of investments					100,000	39,355
Net cash provided by investing activities					97,169	4,334
Cash flows from financing activities:
Proceeds from issuance of Series C convertible preferred stock, net of issuance costs						146,764
Proceeds from exercise of common stock options					16,733	2,232
Payments for the purchase of treasury stock					(11,628)	(163)
Payment of deferred offering costs					(1,613)	(371)
Net cash provided by financing activities					3,492	148,462
Net decrease in cash, cash equivalents, and restricted cash					33,271	94,974
Cash, cash equivalents, and restricted cash at beginning of period		$ 942,711		$ 138,816	942,711	138,816	138,816
Cash, cash equivalents, and restricted cash at end of period	975,982		233,790		975,982	233,790	942,711
Cash, cash equivalents, and restricted cash at end of period:
Cash and cash equivalents	975,187		232,695		975,187	232,695	941,616
Restricted cash	795		1,095		795	1,095
Cash, cash equivalents, and restricted cash at end of period	$ 975,982		$ 233,790		975,982	233,790	$ 942,711
Supplemental disclosure of cash flow information:
Cash paid for income taxes					955	138
Supplemental disclosure of non-cash investing and financing activities:
Additions to property and equipment included in accrued expenses and accounts payable						572
Common stock issuance costs						440
Preferred stock issuance costs						750
Receivable related to exercise of common stock options					$ 71	$ 100

Organization and Description of

Organization and Description of Business	6 Months Ended
	Jun. 30, 2021
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Organization and Description of Business	1. Organization and Description of Business Description of Business American Well Corporation (the “Company”) was incorporated under the laws of the State of Delaware in June 2006. The Company is headquartered in Boston, Massachusetts. The Company is a leading telehealth company that enables the digital distribution and delivery of care for healthcare’s key stakeholders. The Company’s scalable technology is deployed at the enterprise level of clients, embeds into existing offerings and workflows, spans the continuum of care and enables the delivery of this care across a wide variety of clinical, retail, school and home settings. Stock Split On August 28, 2020, the Company effected an 8.8-for-1.0 stock split of its issued and outstanding shares of common stock and a proportional adjustment to the existing conversion ratios for each series of the Company’s then outstanding convertible preferred stock (see Note 10). The corresponding number of shares and exercise prices related to stock options and RSUs were also adjusted. The impact of the stock split has been applied retrospectively to all periods presented. Liquidity and Capital Resources The accompanying condensed consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets, and the satisfaction of liabilities and commitments in the ordinary course of business. On September 21, 2020, the Company closed on the IPO raising $822,267 in gross proceeds. On September 21, 2020, the Company closed on a private placement with Google raising $100,000 in gross proceeds. Since inception, the Company has incurred recurring losses. As of June 30, 2021, the Company had an accumulated deficit of $708,587. The Company expects to continue to generate operating losses for the foreseeable future. The Company expects that its cash, cash equivalents and investments balance as of June 30, 2021 of $975,187 will be sufficient to fund its operating expenses and capital expenditure requirements for at least the next twelve months.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies There have been no material changes to the significant accounting policies described in the Company’s Form 10-K for the fiscal year ended December 31, 2020, that have had a material impact on the consolidated financial statements and related notes. Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (the “SEC”) regarding interim financial reporting. In the opinion of the Company’s management, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting of normal recurring accruals and adjustments) necessary for the fair statement of the Company’s the financial position, results of operations and cash flows at the dates and for the periods indicated. The interim results for the three and six months ended June 30, 2021 are not necessarily indicative of results for the full 2021 calendar year or any other future interim periods. The information included in the interim financial statements should be read in conjunction with the annual consolidated financial statements and accompanying notes included in the Form 10-K. The unaudited condensed consolidated financial statements include the accounts of American Well Corporation, its wholly-owned subsidiaries, those of professional corporations, which represent variable interest entities in which American Well has an interest and is the primary beneficiary (“PC”), and National Telehealth Network (“NTN”), an entity in which American Well controls fifty percent or more of the voting shares (see Note 4). Intercompany accounts and transactions have been eliminated in consolidation. For substantially all of the Company’s subsidiaries, the functional currency is the U.S. dollar. Foreign currency denominated monetary assets and liabilities are remeasured into U.S. dollars at current exchange rates and foreign currency denominated nonmonetary assets and liabilities are remeasured into U.S. dollars at historical exchange rates. Gains or losses from foreign currency remeasurement and settlements are included in interest income and other income (expense), net in the condensed consolidated statements of operations and comprehensive loss. For consolidated entities where American Well owns or is exposed to less than 100% of the economics, the net loss attributable to noncontrolling interests is recorded in the condensed consolidated statements of operations and comprehensive loss equal to the percentage of the economic or ownership interest retained in each entity by the respective non-controlling party. The noncontrolling interests are presented as a separate component of stockholders’ deficit in the condensed consolidated balance sheets. Use of Estimates The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenue and expenses during the reported periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, revenue recognition, the estimated customer relationship period that is used in the amortization of deferred contract acquisition costs, the valuation of assets and liabilities acquired in business combinations, the useful lives of intangible assets and property and equipment and the valuation of common stock. The Company bases its estimates on historical experience, known trends, and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, as there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions. Due to the COVID-19 global pandemic, the global economy and financial markets have been disrupted and there is a significant amount of uncertainty about the length and severity of the consequences caused by the pandemic. The Company has considered information available to it as of the date of issuance of these financial statements and has not experienced any significant impact to its estimates and assumptions as a result of the COVID-19 pandemic. On an ongoing basis, the Company will continue to closely monitor the COVID-19 impact on its estimates and assumptions. Segment Information The Company’s chief operating decision makers (CODMs), its two Chief Executive Officers, review financial information presented on a consolidated basis for purposes of allocating resources and evaluating financial performance. The Company operates and manages its business as one reportable and operating segment. In addition, substantially all of the Company’s revenue and long-lived assets are attributable to operations in the United States for all periods presented. Variable Interest Entities The Company evaluates its ownership, contractual and other interests in entities to determine if it has any variable interest in a variable interest entity (“VIE”). These evaluations are complex and involve judgment. If the Company determines that an entity in which it holds a contractual or ownership interest is a VIE and that the Company is the primary beneficiary, the Company consolidates such entity in its condensed consolidated financial statements. The primary beneficiary of a VIE is the party that meets both of the following criteria: (i) has the power to make decisions that most significantly affect the economic performance of the VIE; and (ii) has the obligation to absorb losses or the right to receive benefits that in either case could potentially be significant to the VIE. Management performs ongoing reassessments of whether changes in the facts and circumstances regarding the Company’s involvement with a VIE will cause the consolidation conclusion to change. Changes in consolidation status are applied prospectively. The aggregate carrying value of total assets and total liabilities included on the condensed consolidated balance sheets for the PCs after elimination of intercompany transactions were $30,207 and $1,929, respectively, as of June 30, 2021 and $22,682 and $1,998, respectively as of December 31, 2020. Total revenue included on the condensed consolidated statements of operations and comprehensive loss for the PCs after elimination of intercompany transactions was $17,585 and $24,719 for the three months ended June 30, 2021 and 2020, respectively. Net loss included on the condensed consolidated statements of operations and comprehensive loss was not material for the three months ended June 30, 2021 and 2020. Total revenue included on the condensed consolidated statements of operations and comprehensive loss for the PCs after elimination of intercompany transactions was $35,154 and $43,389 for the six months ended June 30, 2021 and 2020, respectively. Net loss included on the condensed consolidated statements of operations and comprehensive loss was not material for the three and six months ended June 30, 2021 and 2020. Investment in Minority Owned Joint Venture The Company and Cleveland Clinic partnered to form a joint venture, under the name CCAW, JV LLC, to provide broad access to comprehensive and high acuity care services via telehealth. The Company does not have a controlling financial interest in CCAW, JV LLC, but it does have the ability to exercise significant influence over the operating and financial policies of CCAW, JV LLC. Therefore, the Company accounts for its investment in CCAW, JV LLC using the equity method of accounting. The joint venture is considered a variable interest entity under ASC 810-10, but the Company is not the primary beneficiary as it does not have the power to direct the activities of the joint venture that most significantly impact its performance. The Company’s evaluation of ability to impact performance is based on Cleveland Clinic’s managing directors and Cleveland Clinic’s ability to appoint and remove the chairperson who has the ability to cast the tie breaking vote on the most significant activities. In 2020 the Company contributed $2,940 as its initial investment for a 49% interest in CCAW, JV LLC. The agreement also requires aggregate total capital contributions by the Company up to an additional $11,800 in two phases, which is yet to be defined. During the six months ended June 30, 2021, the Company made a capital contribution of $2,548, related to a portion of the phase one capital commitment. For the three months ended June 30, 2021 and 2020, the Company recognized a loss of $722 and $444 as its proportionate share of the joint venture’s results of operations, respectively. For the six months ended June 30, 2021 and 2020, the Company recognized a loss of $1,541 and $764 as its proportionate share of the joint venture’s results of operations, respectively. Accordingly, the carrying value of the equity method investment as of June 30, 2021 and December 31, 2020 was $1,759 and $752, respectively. Concentrations of Credit Risk and Significant Customers Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, cash equivalents, investments and accounts receivable. The Company invests its excess cash with large financial institutions that the Company believes are of high credit quality. Cash and cash equivalents are invested in highly rated money market funds. At times, the Company’s cash balances with individual banking institutions are in excess of federally insured limits. The Company’s investments are invested in U.S. government agency bonds. The Company has not experienced any losses on its deposits of cash, cash equivalents or investments. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. The Company performs ongoing assessments and credit evaluations of its customers to assess the collectability of the accounts based on a number of factors, including past transaction experience, age of the accounts receivable, review of the invoicing terms of the contracts, and recent communication with customers. The Company has not experienced significant credit losses from its accounts receivable. As of June 30, 2021 and December 31, 2020, one customer accounted for 14% and 19% of outstanding accounts receivable, respectively. During the three months ended June 30, 2021 and 2020, sales to one customer (who was a related party during the 2020 period noted) represented 25% and 22% of the Company’s total revenue, respectively. During the six months ended June 30, 2021 and 2020, sales to one customer (who was a related party during the periods noted) represented 25% and 22% of the Company’s total revenue, respectively. Emerging Growth Company Status The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with certain new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it is (i) no longer an emerging growth company or (ii) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. Recently Adopted Accounting Pronouncements In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Requirements for Fair Value Measurement In August 2018, the FASB issued ASU 2018-15, Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which simplifies the accounting for income taxes by removing certain exceptions and clarifying and amending existing guidance. ASU 2019-12 removes certain exceptions for performing intraperiod tax allocations, recognizing deferred taxes for investments, and calculating income taxes in interim periods. The guidance also simplifies the accounting for franchise taxes, transactions that result in a step-up in the tax basis of goodwill, and the effect of enacted changes in tax laws or rates in interim periods. For public entities that are Securities and Exchange Commission filers, excluding entities eligible to be smaller reporting companies, ASU 2019-12 is effective for annual periods beginning after December 15, 2020, including interim periods within those fiscal years. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2021, and interim periods within fiscal years beginning after December 15, 2022. Early adoption is permitted. The guidance was adopted effective January 1, 2021 and did not have a material impact on the condensed consolidated financial statements and disclosures. Recently Issued Accounting Pronouncements In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments Codification Improvements to Topic 326, Financial Instruments—Credit Losses Financial Instruments—Credit Losses (Topic 326): Targeted Transition Relief are Securities and Exchange Commission filers, excluding entities eligible to be smaller reporting companies, ASU 2016-13 is effective for annual periods beginning after December 15, 2019, including interim periods within those fiscal years. For all other entities, ASU 2016-13 is effective for annual periods beginning after December 15, 2022, including interim periods within those fiscal years. Early adoption is permitted. Th e guidance will be adopted in the 2021 annual condensed consolidated financial statements. The Company is currently evaluating the impact that the adoption of ASU 2016-13 will have on its condensed consolidated financial statements.

Revenue

Revenue	6 Months Ended
	Jun. 30, 2021
Revenue From Contract With Customer [Abstract]
Revenue	3. Revenue The following table presents the Company’s revenues disaggregated by revenue source: Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Platform subscription $ 26,780 $ 24,458 $ 51,376 $ 46,214 Visits 27,532 36,017 55,353 62,481 Other 5,905 8,093 11,087 13,587 Total Revenue $ 60,217 $ 68,568 $ 117,816 $ 122,282 Accounts Receivable, Net Accounts receivable primarily consist of amounts billed currently due from customers. Accounts receivable are presented net of an allowance for doubtful accounts, which is an estimate of amounts that may not be collectible. In determining the amount of the allowance at each reporting date, the Company makes judgments about general economic conditions, historical write-off experience and any specific risks identified in customer collection matters, including the aging of unpaid accounts receivable and changes in customer financial conditions. Account balances are written off after all means of collection are exhausted and the potential for non-recovery is determined to be probable. Adjustments to the allowance for doubtful accounts are recorded as general and administrative expenses in the condensed consolidated statements of operations and comprehensive loss. Changes in the allowance for doubtful accounts were as follows: Six Months Ended June 30, Year Ended December 31, 2020 Allowance for doubtful accounts, beginning of the period $ 1,556 $ 686 Provisions (57 ) 1,646 Write-offs (460 ) (776 ) Allowance for doubtful accounts, end of the period $ 1,039 $ 1,556 The Company has rights to consideration for services completed but not billed at the reporting date. Unbilled receivables are classified as receivables when the Company has the right to invoice the customer. The amount of unbilled accounts receivable was $3,387 and $3,376 as of June 30, 2021 and December 31, 2020, and has been included within accounts receivable on the condensed consolidated balance sheet. Deferred Revenue Contract liabilities consist of deferred revenue and include billings in advance of performance under the contract. Such amounts are recognized as revenue over the contractual period. For the three months ended June 30, 2021 and 2020, the Company recognized revenue of $21,238 and $18,985, respectively, that was included in the corresponding contract liability balance at the beginning of the periods presented. For the six months ended June 30, 2021 and 2020, the Company recognized revenue of $39,146 and $41,731, respectively, that was included in the corresponding contract liability balance at the beginning of the periods presented. Significant changes in the Company’s deferred revenue balance for the six months ended June 30, 2021 and the year ended December 31, 2020 were as follows: Six Months Ended June 30, Year Ended December 31, 2020 Total deferred revenue, beginning of the period $ 74,800 $ 77,386 Additions 45,487 109,542 Recognized (54,921 ) (112,128 ) Total deferred revenue, end of the period $ 65,366 $ 74,800 Current deferred revenue 57,836 66,693 Non-current deferred revenue 7,530 8,107 Total $ 65,366 $ 74,800 Transaction Price Allocated to Remaining Performance Obligations As of June 30, 2021 and December 31, 2020, the aggregate amount of the transaction price allocated to remaining performance obligations was $190,413 and $192,238, respectively. The substantial majority of the unsatisfied performance obligations will be satisfied over the next three years. As it pertains to the June 30, 2021 amount, the Company expects to recognize 47% of the transaction price in the 12 month period ended June 30, 2022, in its condensed consolidated statement of operations and comprehensive loss with the remainder recognized thereafter.

National Telehealth Network

National Telehealth Network	6 Months Ended
	Jun. 30, 2021
Equity Method Investments And Joint Ventures [Abstract]
National Telehealth Network	4. National Telehealth Network In 2012, the Company and an affiliate of Anthem, Inc. formed NTN to expand the availability and adoption of telemedicine. The Company did not have a controlling financial interest in NTN, but it had the ability to exercise significant influence over the operating and financial policies of NTN. Therefore, the Company accounted for its investment in NTN using the equity method of accounting through December 31, 2015. On January 1, 2016, the Company made an additional investment in NTN, which increased its ownership percentage above 50%. The Company also obtained the right to elect the Chairman of NTN, who has the ability to cast the tie-breaking vote in all decisions. Therefore, on January 1, 2016, the Company obtained control over NTN and has the power to direct the activities that most significantly impact NTN’s economic performance. This step-acquisition was accounted for as a business combination and the results of the operations of NTN from January 1, 2016, have been included in the Company’s condensed consolidated financial statements. However, because the Company owns less than 100% of NTN, the Company recognizes net loss attributable to non-controlling interest in the condensed consolidated statements of operations and comprehensive loss equal to the percentage of the ownership interest retained in NTN by the respective non-controlling party. The proportionate share of the loss attributed to the non-controlling interest amounted to $277 and $1,562 for the three months ended June 30, 2021 and 2020, respectively. The proportionate share of the loss attributed to the non-controlling interest amounted to $894 and $2,405 for the six months ended June 30, 2021 and 2020, respectively. The carrying value of the non-controlling interest was $21,171 and $22,065 as of June 30, 2021 and December 31, 2020, respectively.

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2021
Fair Value Disclosures [Abstract]
Fair Value Measurements	5. Fair Value Measurements Certain assets and liabilities of the Company are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: • Level 1—Quoted prices in active markets for identical assets or liabilities. • Level 2—Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. • Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. The following tables presents the Company’s fair value hierarchy for its assets and liabilities that are measured at fair value on a recurring basis and indicate the level within the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value: June 30, 2021 Level 1 Level 2 Level 3 Total Money market funds $ 814,087 $ — $ — $ 814,087 Investments — — — $ — $ 814,087 $ — $ — $ 814,087 December 31, 2020 Level 1 Level 2 Level 3 Total Money market funds $ 892,934 $ — $ — $ 892,934 Investments — 99,963 — 99,963 $ 892,934 $ 99,963 $ — $ 992,897 The Company’s cash equivalents were invested in money market funds and were valued based on Level 1 inputs. The Company’s investments consisted of U.S. government agency bonds and were valued based on Level 2 inputs. In determining the fair value of its U.S. government agency bonds, the Company relied on quoted prices for similar securities in active markets or other inputs that are observable or can be corroborated by observable market data. During the six months ended June 30, 2021, there were no transfers between fair value measurement levels.

Investments

Investments	6 Months Ended
	Jun. 30, 2021
Investments Debt And Equity Securities [Abstract]
Investments	6. Investments As of June 30, 2021 and December 31, 2020, the fair value of the Company’s investments by type of security was as follows: June 30, 2021 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Assets: U.S government securities $ — $ — $ — $ — $ — $ — $ — $ — December 31, 2020 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Assets: U.S government securities $ 99,854 $ 109 $ — $ 99,963 $ 99,854 $ 109 $ — $ 99,963

Goodwill and Intangible Assets

Goodwill and Intangible Assets	6 Months Ended
	Jun. 30, 2021
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	7. Goodwill and Intangible Assets Goodwill consisted of the following: Six Months Ended June 30, Year Ended December 31, 2020 Beginning Balance as of January 1 $ 193,877 $ 193,877 Goodwill acquired — — Ending Balance $ 193,877 $ 193,877 Identified intangible assets consisted of the following: Gross Amount Accumulated Amortization Carrying Value Weighted Average Remaining Life June 30, 2021 Customer relationships $ 38,782 $ (13,363 ) $ 25,419 6.5 Contractor relationships 535 (226 ) $ 309 7.5 Technology 37,063 (11,119 ) $ 25,944 7.0 $ 76,380 $ (24,708 ) $ 51,672 Gross Amount Accumulated Amortization Carrying Value Weighted Average Remaining Life December 31, 2020 Customer relationships $ 38,782 $ (11,380 ) $ 27,402 7.0 Contractor relationships 535 (206 ) 329 8.0 Trade name 300 (300 ) — — Technology 37,063 (9,266 ) 27,797 7.5 $ 76,680 $ (21,152 ) $ 55,528 Amortization expense related to intangible assets for the three months ended June 30, 2021 and 2020 was $1,928 and $1,938, respectively. Amortization expense related to intangible assets for the six months ended June 30, 2021 and 2020 was $3,856 and $3,877, respectively. Estimated future amortization expense of the identified intangible assets as of June 30, 2021, is as follows: 2021 $ 3,856 2022 7,712 2023 7,712 2024 7,712 2025 7,712 Thereafter 16,968 $ 51,672

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	6 Months Ended
	Jun. 30, 2021
Payables And Accruals [Abstract]
Accrued Expenses and Other Current Liabilities	8. Accrued Expenses and other current liabilities Accrued expenses and other current liabilities consist of the following: Six Months Ended June 30, Year Ended December 31, 2020 Employee compensation and benefits $ 10,059 $ 20,521 Professional services 3,763 6,832 Provider services 3,937 4,632 Other 7,105 10,150 Total $ 24,864 $ 42,135

Line of Credit

Line of Credit	6 Months Ended
	Jun. 30, 2021
Debt Disclosure [Abstract]
Line of Credit	9. Line of Credit In January 2011, the Company entered into a credit agreement (the “Line of Credit”) with a financial institution that provides for maximum borrowings in one or more advances of an amount up to $5,000. Borrowings under the Line of Credit accrue interest at the London Interbank Offered Rate plus 1.25%. Borrowings are repayable immediately upon demand by the financial institution. In November 2017, the Line of Credit was amended to increase the maximum borrowings to $7,000. As of June 30, 2021 and December 31, 2020, the Company had no outstanding borrowings under the Line of Credit. During any period that the Line of Credit is in effect, the Company can request the financial institution issue a letter of credit with a maximum maturity not to exceed twelve months. Any letters of credit issued by the financial institution reduce the maximum borrowings available under the Line of Credit. As of June 30, 2021, the maximum borrowing available to the Company is $6,205 based on the outstanding letters of credit of $795 that have been issued by the financial institution. As of December 31, 2020, the maximum borrowing available to the Company was $5,905 based on the outstanding letters of credit of $1,095 that have been issued by the financial institution.

Stockholders' Equity

Stockholders' Equity	6 Months Ended
	Jun. 30, 2021
Stockholders Equity Note [Abstract]
Stockholders' Equity	10. Stockholders’ Equity Convertible Preferred Stock The authorized, issued and outstanding shares, liquidation preference, and carrying value of the Company’s convertible preferred stock as of December 31, 2019 were as follows: Shares Authorized Shares Issued Shares Outstanding Liquidation Preference Carrying Value Series A 3,200,000 3,178,650 3,130,077 51,741 28,889 Series B 833,334 787,725 787,725 37,060 23,632 Series C 13,711,111 10,095,133 10,095,133 519,648 603,278 17,744,445 14,061,508 14,012,935 608,449 655,799 In February 2020, the Company issued and sold 170,000 shares of Series C preferred stock at a price of $75 per share for gross proceeds of $12,750. The Company incurred $261 of issuance costs in connection with the issuance of the Series C preferred stock In May 2020, the Company issued and sold 1,342,750 shares of Series C preferred stock at a price of $100 per share for gross proceeds of $134,275. The Company incurred $750 of issuance costs in connection with the issuance of the Series C preferred stock. In conjunction with the Company’s IPO in September 2020, all shares of convertible preferred stock then outstanding, totaling 15,525,685 shares (pre-split), were automatically converted into an equivalent number of shares of Class A common stock on an 8.8-to-1.0 basis pursuant to a stock split and their carrying value, totaling $801,813 was reclassified into stockholders’ equity on the condensed consolidated balance sheet. In connection with the IPO, the Company filed an Amended and Restated Certificate of Incorporation which authorizes the issuance of 100,000,000 shares of undesignated preferred stock, par value of $0.01 per share, with rights and preferences, including voting rights, designated from time to time by the board of directors. Common Stock In September 2020, upon completion of the IPO, the Company sold 45,681,499 shares of Class A common stock at an offering price of $18.00 per share, including 4,459,277 shares of Class A common stock pursuant to the exercise in full of the underwriters’ option to purchase additional shares. The Company received net proceeds of $767,568, after deducting underwriting discounts and commissions of $49,336 and offering costs of approximately $4,906. In September 2020, the Company sold 5,555,555 shares of Class C common stock in connection with the stock purchase agreement with Google, LLC for net proceeds of $99,100, after deducting offering costs of $900. Concurrently with the IPO, the Company used $24,157 of the proceeds from the IPO to repurchase 1,340,354 shares of Class A and Class B common stock from certain executive officers and other employees, to permit such executive officers and other employees to pay taxes owed in connection with the vesting of equity awards, including the repayment of third-party loans incurred to finance the payment of such taxes. In connection with the IPO, the Company filed an Amended and Restated Certificate of Incorporation which authorizes capital stock of 1,000,000,000 shares of Class A common stock, par value $0.01 per share, 100,000,000 shares of Class B common stock, par value $0.01 per share, and 200,000,000 shares of Class C common stock, par value $0.01 per share. Except for the rights noted below, each share of Class A, Class B and Class C common stock have the same rights, are equal in all respects and are treated by us as one class of shares. Each share of Class A and Class C common stock is entitled to one vote per share on all matters presented for a vote, except that Class C common stock does not have the right to vote for elections of directors. Subject to certain conditions, Class B common stock is collectively entitled to a number of votes equal to the product of (x) 1.0408163 and (y) the total number of votes that would be cast at such time by the holders of the Class A and Class C common stock and any other preferred stock entitled to vote under the certificate of incorporation at such time (resulting in the Class B common stock collectively holding 51% of the total outstanding voting power), and each share of Class B common stock will be entitled to a number of votes equal to the total number of votes held by all Class B common stock divided by the total number of then outstanding shares of Class B common stock. Shares of Class B and Class C common stock will be converted into shares of Class A common stock on a one-for-one basis upon the occurrence of certain events. Shares of Class B common stock will automatically convert on the first business day (i) after the date on which the outstanding shares of Class B common stock constitutes less than 5% of the aggregate number of shares of common stock then outstanding, (ii) after the date on which neither founder is serving as an executive officer or (iii) following seven years after the date the amended and restated certificate of incorporation becomes effective, provided that, such period may, to the extent permitted by law and applicable stock exchange rules, be extended for three years upon the affirmative vote of the holders of a majority of the voting power of the then-outstanding shares of Class A common stock entitled to vote thereon, voting separately as a class. Shares of Class C common stock will be convertible at the option of the holder upon determination that a Hart-Scott-Rodino Antitrust Improvements Act (“HSR”) filing is not necessary prior to the holder’s conversion of such shares or, if required, upon expiration or termination of the HSR waiting period. In the six months ended June 30, 2021, 3,351,035 shares of Class B common stock were converted to Class A common stock. As of June 30, 2021, the par value of the Class A, Class B and Class C shares was $2,099, $267, and $56, respectively. Shares Authorized Shares Issued Shares Outstanding Class A 1,000,000,000 209,875,389 209,875,389 Class B 100,000,000 26,687,959 26,687,959 Class C 200,000,000 5,555,555 5,555,555 1,300,000,000 242,118,903 242,118,903 As of June 30, 2021 and December 31, 2020, the Company had reserved 66,187,346 and 61,392,747 shares of common stock for the exercise of outstanding stock options, the vesting of restricted stock units and the number of shares remaining available for future grant, respectively. Stock Plans and Stock Options The Company maintains the 2006 Employee, Director and Consultant Stock Plan as amended and restated (the “2006 Plan”) and 2020 Equity Incentive Plan (the “2020 Plan” together, the “Plans”) under which it has granted incentive stock options, non-qualified stock options, and restricted stock units to employees, officers, and directors of the Company. In connection with the adoption of the 2020 Plan, the then-remaining shares of common stock reserved for grant or issuance under the 2006 Plan became available for issuance under the 2020 Plan, and no further grants will be made under the 2006 Plan. The 2020 Plan is administered by the board of directors with respect to awards to non-employee directors and by the compensation committee, with respect to other participants, are collectively, referred to as the plan administrator. The exercise prices, vesting and other restrictions are determined at the discretion of the plan administrator. Options issued under the Plans are exercisable for periods not to exceed ten years, and vest and contain such other terms and conditions as specified in the applicable award document. Options to buy common stock are issued under the Plans, with exercise prices equal to the closing price of shares of the Company’s common stock on the New York Stock Exchange on the date of award. Activity under the Plans is as follows: Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Outstanding as of January 1, 2021 23,167,514 $ 4.37 6.2 $ 487,758 Granted — $ — Forfeited (317,894 ) $ 5.70 Expired — $ — Exercised (5,286,866 ) $ 3.25 Outstanding as of June 30, 2021 17,562,754 4.68 6.2 $ 140,880 Vested and expected to vest as of December 31, 2020 21,744,937 $ 4.14 6.0 $ 460,712 Vested and expected to vest as of June 30, 2021 16,685,854 $ 4.46 6.1 $ 135,479 Options exercisable as of December 31, 2020 17,640,827 $ 3.71 5.5 $ 381,511 Options exercisable as of June 30, 2021 13,809,991 $ 4.13 5.7 $ 116,756 No options were granted in the six months ended June 30, 2021. The weighted-average grant date fair value of common stock options granted during the six months ended June 30, 2020 was $3.88. The weighted-average of assumptions that the Company used to determine the fair value of the common stock options granted to employees and directors were as follows: Six Months Ended June 30, 2021 2020 Risk-free interest rate N/A 1.32 % Expected term (in years) N/A 6.1 Expected volatility N/A 51 % Expected dividend yield N/A 0 % Executive Equity Awards Each CEO has received restricted stock units, equaling 1.5% of the Company’s fully-diluted outstanding capital stock as a result of the IPO (“IPO RSUs”), 50% of the IPO RSUs (representing 0.75% of the Company’s fully diluted outstanding capital stock immediately prior to the IPO or 3,230,750 shares of Class A common stock) were granted on the closing date of the IPO based on the closing price per share on the IPO closing date, and 50% (representing 0.75% of the Company’s fully diluted outstanding capital stock immediately prior to the IPO or 3,230,750 shares of Class A common stock) was granted on the 180-day anniversary of the IPO, based on a specific range of the price per share of the Company’s publicly traded common stock prior March 16, 2021, and will vest over a three-year period, with one-third vesting on the first anniversary of the IPO’s closing date and the remaining vesting in equal quarterly installments thereafter. As the issuance of the second 50% tranche was based upon events that are probable the expense related to both tranches of the IPO RSUs was recognized in the three months ended September 30, 2020. The grant-date fair value of each of the awards issued on the IPO closing date and issued on the 180-day anniversary of the IPO was estimated using a binomial lattice approach. The main inputs to valuing the IPO RSUs include the fair value of Class A common stock ($9.96 post-split), expected volatility (60%) and the expected date of the IPO (September 30, 2020). The Company recognized a total of $23,644 in stock-based compensation expense, which included both tranches of the IPO RSUs for each CEO, on the date of the IPO as the requisite future service of the awards is not substantive for accounting purposes. Restricted Stock Units During the year ended December 31, 2020, the Company granted 13,816,885 restricted stock units which vest over the service period of one to four years. During the six months ended June 30, 2021, the Company granted 6,409,182 restricted stock units which vest over the service period of one to four years. Activity for the restricted stock units is as follows: Shares Weighted Average Grant Date Fair Value Unvested as of January 1, 2021 11,014,450 $ 14.43 Granted 6,409,182 19.95 Vested (1,698,742 ) 9.56 Forfeited (108,946 ) 15.75 Unvested as of June 30, 2021 15,615,944 $ 17.22 The total grant date fair value of RSU’s granted for the six months ended June 30, 2021 was $127,834. During the six months ended June 30, 2020 the Company granted 2,616,345 restricted stock units. The aggregate intrinsic value of restricted stock units vested for the six months ended June 30, 2021 and 2020 was $35,223 and $1,693, respectively. 2020 Employee Stock Purchase Plan In July and August 2020, the Company’s board of directors adopted, and the Company’s stockholders approved, the 2020 Employee Stock Purchase Plan (“ESPP”). A total of 3,084,218 shares of Class A common stock were reserved for issuance under the ESPP. The ESPP became effective March 1, 2021. Rights granted under the ESPP will be issued only with respect to shares of Class A common stock. The purchase price of the shares will not be less than 85% of the fair market value of Class A common stock on the lower of the purchase date, which will be the final trading day of the purchase period, or the enrollment date, which will be the first trading day of the offering period. As of June 30, 2021, the Company had not issued any shares under the ESPP and the total 3,084,218 shares remained available for issuance. For the three and six months ended June 30, 2021, the Company recorded stock-based compensation expense related to the ESPP of $281 and $384, respectively, based on elections made under the plan to-date. There was no expense for the three and six months ended June 30, 2020. Stock-Based Compensation Stock-based compensation expense was classified in the condensed consolidated statements of operations and comprehensive loss as follows: Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Cost of revenues $ 521 $ 168 $ 910 $ 359 Research and development 2,171 988 3,678 1,436 Selling and marketing 2,100 756 3,989 1,546 General and administrative 5,934 65,726 10,791 68,755 Total $ 10,726 $ 67,638 $ 19,368 $ 72,096 As of June 30, 2021, the unrecognized stock-based compensation expense related to unvested common stock-based awards was $88,396, which is expected to be recognized over a weighted-average period of 3 years.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2021
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	11. Commitments and Contingencies Indemnification The Company’s arrangements generally include certain provisions for indemnifying customers against third-party claims asserting infringement of certain intellectual property rights in the ordinary course of business. The Company also regularly indemnifies customers against third-party claims that the company’s products or services breach applicable law or regulation or from claims resulting from a breach of the business associate agreement in place with the customer. In addition, the Company indemnifies its officers, directors and certain key employees while they are serving in good faith in their capacities. Through June 30, 2021 and December 31, 2020, there have been no claims under any indemnification provisions. Litigation From time to time, and in the ordinary course of business, the Company may be subject to various claims, charges, and litigation. On September 14, 2020, the Company received a letter from Teladoc Health, Inc. alleging that certain of the Company’s cart products and associated peripherals infringe upon their patents. On October 12, 2020, Teladoc Health, Inc filed a claim against the Company related to these allegations. The Company believes that these claims lack merit and intends to defend against them vigorously. As of June 30, 2021 and December 31, 2020, the Company did not have any pending claims, charges or litigation that it expects would have a material adverse effect on its consolidated financial position, results of operations or cash flows.

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2021
Income Tax Disclosure [Abstract]
Income Taxes	12. Income Taxes As a result of the Company’s history of net operating losses (“NOL”), the Company has provided for a full valuation allowance against its domestic deferred tax assets. For the three and six months ended June 30, 2021, the Company recognized an income tax expense of $103 and $412, primarily due to estimated state and foreign income taxes. During the three and six months ended June 30, 2020, the Company recorded income tax expense of $252.

Related-Party Transactions

Related-Party Transactions	6 Months Ended
	Jun. 30, 2021
Related Party Transactions [Abstract]
Related-Party Transactions	13. Related-Party Transactions Teva Pharmaceuticals, Industries Ltd Teva Pharmaceuticals, Industries Ltd (“Teva”) is a related party because a member of the Company’s board of directors was the President and CFO of Teva Pharmaceuticals’ North America Commercial. In addition, Teva is a shareholder of the Company. As of June 30, 2021 and December 31, 2020, short-term and long-term deferred revenue from this customer was not material. As of June 30, 2021 and December 31, 2020, amounts due from Teva were not material. During the three and six months ended June 30, 2021 and 2020, revenues recognized from this customer were not material. Philips Holding USA, Inc. Philips Holding USA, Inc. (“Philips”) is a related party because a member of the Company’s board of directors is the Business Leader of Philips Population Health Management. In addition, Philips is a non-significant shareholder of the Company. As of June 30, 2021 and December 31, 2020, the Company held short-term and long-term deferred revenue of $977 and $2,549, respectively from contracts with this customer. As of June 30, 2021 and December 31, 2020, amounts due from Philips were $547 and $763, respectively. During the three months ended June 30, 2021 and 2020, the Company recognized revenue of $758 and $368, respectively from contracts with this customer. During the six months ended June 30, 2021 and 2020, the Company recognized revenue of $1,658 and $708, respectively from contracts with this customer. Anthem Inc. Anthem Inc. (“Anthem”) was determined to be a related party because a member of the Company’s board of directors served as the Vice President of Anthem through February 2021. In addition, Anthem is a non-significant shareholder of the Company. As of June 30, 2021 it was determined Anthem was no longer a related party. As of December 31, 2020, the Company held short-term and long-term deferred revenue of $ , from contracts with this customer. As of December 31, 20 20 , amounts due from Anthem were $ 8,391 . Prior to the board member’s departure from Anthem in February 2021, the Company recognized revenue of $7,218 from contracts with this customer. During the three and six months ended June 30, 2020 the Company recognized revenue of $14,848 and $27,155, respectively from contracts with this customer. Cleveland Clinic Cleveland Clinic is a related party because a member of the Company’s board of directors is an executive advisor to Cleveland Clinic. As of June 30, 2021 and December 31, 2020, the Company held short-term and long-term deferred revenue of $451 and $606, respectively from contracts with this customer. As of June 30, 2021 and December 31, 2020, amounts due from Cleveland Clinic were $85 and $1,020, respectively. During the three months ended June 30, 2021 and 2020, the Company recognized revenue of $279 and $294, respectively, from contracts with this customer. During the six months ended June 30, 2021 and 2020, the Company recognized revenue of $530 and $490, respectively, from contracts with this customer. CCAW, JV LLC CCAW, JV LLC is a related party because it is a joint venture formed between the Company and Cleveland Clinic for which the Company has a minority owned interest in. During the year ended December 31, 2020, the Company made an initial investment in CCAW, JV LLC of $2,940 for its less than 50% interest in the joint venture. During the six months ended June 30, 2021, the Company made a capital contributed of $2,548, related to a portion of the phase one capital commitment. During the three months ended June 30, 2021 and 2020 the Company recognized revenue of $412 and $393 from contracts with this customer, respectively. During the six months ended June 30, 2021 and 2020 the Company recognized revenue of $874 and $786 from contracts with this customer, respectively, As of June 30, 2021 and December 31, 2020, the Company held short and long term deferred revenue of $840 and $1,496, respectively, from contracts with this customer. As of June 30, 2021 and December 31, 2020, amounts due from CCAW, JV LLC were not material. Loans to Officers During 2020, the Company entered into secured promissory notes with executive officers in the amount of $16,441. These loans were to fund the taxes associated with the restricted stock units and were collateralized by all of the capital stock of the Company that the employee owned or would own in the future and the employees’ personal assets. These loans are recorded within prepaids and other current assets in the Company’s condensed consolidated balance sheet. All outstanding loans with officers were repaid in August 2020 prior to the Company’s IPO.

Net Loss per Share

Net Loss per Share	6 Months Ended
	Jun. 30, 2021
Earnings Per Share [Abstract]
Net Loss per Share	14. Net Loss per Share Basic and diluted net loss per share attributable to common stockholders was calculated as follows: Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Numerator: Net loss $ (38,136 ) $ (88,220 ) $ (77,941 ) $ (113,444 ) Net loss attributable to non-controlling interest (277 ) (1,562 ) (894 ) (2,405 ) Net loss attributable to American Well Corporation $ (37,859 ) $ (86,658 ) $ (77,047 ) $ (111,039 ) Denominator: Weighted-average common shares outstanding —basic and diluted 249,366,652 43,484,313 246,471,733 41,793,108 Net loss per share attributable to common stockholders—basic and diluted $ (0.15 ) $ (1.99 ) $ (0.31 ) $ (2.66 ) The Company’s potential dilutive securities, which include stock options, convertible preferred stock and unvested restricted stock units, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following potential common shares equivalents presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect: Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Convertible preferred stock (as converted to common stock) — 136,625,900 — 136,625,900 Unvested restricted stock units 7,724,006 2,028,461 7,724,006 2,028,461 Options to purchase shares of common stock 17,562,754 25,033,565 17,562,754 25,033,565 25,286,760 163,687,926 25,286,760 163,687,926

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2021
Subsequent Events [Abstract]
Subsequent Events	15. Subsequent Events On July 27, 2021 and July 28, 2021 the Company entered into two separate purchase agreements to acquire Conversa Health Inc. (“Conversa”) and SilverCloud Health Holdings, Inc. (“SilverCloud”), respectively. Conversa is a leader in automated virtual healthcare. SilverCloud is a leading digital mental health platform. By adding the technology of these two companies to its virtual care platform, Amwell is enhancing the differentiated value it can bring to current and future clients. Under the terms of the agreement with Conversa, the aggregate purchase price of approximately $110,000 will consist of approximately $55,000 in cash and $55,000 in Amwell stock (4.7 million shares). Under the terms of the agreement with SilverCloud, the aggregate purchase price of approximately $210,000 will consist of approximately $110,000 in cash and $100,000 in Amwell stock (8.5 million shares). As this transaction has not yet closed, the mix of cash and stock consideration could change. The aggregate consideration for Conversa could increase by $30,000 subject to financial performance over a twelve-month period paid all in stock. The aggregate consideration for SilverCloud could increase by $40,000 subject to financial and operational performance over a twelve-month period paid all in stock. Conversa closed on August 10, 2021 and SilverCloud is expected to close by the end of the third quarter of 2021. The Company expects to determine the preliminary purchase allocation prior to the end of the third quarter of 2021. On July 19, 2021, the Company entered into an Employment Agreement (the “Employment Agreement”) with Brendan O’Grady to become the Company’s Chief Commercial & Growth Officer, effective August 16, 2021. Pursuant to the Employment Agreement, Mr. O’Grady will receive an annual base salary of $485 and will be eligible for an annual target bonus of 200% of his annual base salary. In addition, Mr. O’Grady will receive a grant of restricted stock units with a grant date value of $8,000 that settle in shares of the Company’s Class A common stock, with 25% of the restricted stock units being vested on the grant date, and the remaining vesting ratably every 3 months thereafter over a four-year

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (the “SEC”) regarding interim financial reporting. In the opinion of the Company’s management, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting of normal recurring accruals and adjustments) necessary for the fair statement of the Company’s the financial position, results of operations and cash flows at the dates and for the periods indicated. The interim results for the three and six months ended June 30, 2021 are not necessarily indicative of results for the full 2021 calendar year or any other future interim periods. The information included in the interim financial statements should be read in conjunction with the annual consolidated financial statements and accompanying notes included in the Form 10-K. The unaudited condensed consolidated financial statements include the accounts of American Well Corporation, its wholly-owned subsidiaries, those of professional corporations, which represent variable interest entities in which American Well has an interest and is the primary beneficiary (“PC”), and National Telehealth Network (“NTN”), an entity in which American Well controls fifty percent or more of the voting shares (see Note 4). Intercompany accounts and transactions have been eliminated in consolidation. For substantially all of the Company’s subsidiaries, the functional currency is the U.S. dollar. Foreign currency denominated monetary assets and liabilities are remeasured into U.S. dollars at current exchange rates and foreign currency denominated nonmonetary assets and liabilities are remeasured into U.S. dollars at historical exchange rates. Gains or losses from foreign currency remeasurement and settlements are included in interest income and other income (expense), net in the condensed consolidated statements of operations and comprehensive loss. For consolidated entities where American Well owns or is exposed to less than 100% of the economics, the net loss attributable to noncontrolling interests is recorded in the condensed consolidated statements of operations and comprehensive loss equal to the percentage of the economic or ownership interest retained in each entity by the respective non-controlling party. The noncontrolling interests are presented as a separate component of stockholders’ deficit in the condensed consolidated balance sheets.
Use of Estimates	Use of Estimates The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenue and expenses during the reported periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, revenue recognition, the estimated customer relationship period that is used in the amortization of deferred contract acquisition costs, the valuation of assets and liabilities acquired in business combinations, the useful lives of intangible assets and property and equipment and the valuation of common stock. The Company bases its estimates on historical experience, known trends, and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, as there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions. Due to the COVID-19 global pandemic, the global economy and financial markets have been disrupted and there is a significant amount of uncertainty about the length and severity of the consequences caused by the pandemic. The Company has considered information available to it as of the date of issuance of these financial statements and has not experienced any significant impact to its estimates and assumptions as a result of the COVID-19 pandemic. On an ongoing basis, the Company will continue to closely monitor the COVID-19 impact on its estimates and assumptions.
Segment Information	Segment Information The Company’s chief operating decision makers (CODMs), its two Chief Executive Officers, review financial information presented on a consolidated basis for purposes of allocating resources and evaluating financial performance. The Company operates and manages its business as one reportable and operating segment. In addition, substantially all of the Company’s revenue and long-lived assets are attributable to operations in the United States for all periods presented.
Variable Interest Entities	Variable Interest Entities The Company evaluates its ownership, contractual and other interests in entities to determine if it has any variable interest in a variable interest entity (“VIE”). These evaluations are complex and involve judgment. If the Company determines that an entity in which it holds a contractual or ownership interest is a VIE and that the Company is the primary beneficiary, the Company consolidates such entity in its condensed consolidated financial statements. The primary beneficiary of a VIE is the party that meets both of the following criteria: (i) has the power to make decisions that most significantly affect the economic performance of the VIE; and (ii) has the obligation to absorb losses or the right to receive benefits that in either case could potentially be significant to the VIE. Management performs ongoing reassessments of whether changes in the facts and circumstances regarding the Company’s involvement with a VIE will cause the consolidation conclusion to change. Changes in consolidation status are applied prospectively. The aggregate carrying value of total assets and total liabilities included on the condensed consolidated balance sheets for the PCs after elimination of intercompany transactions were $30,207 and $1,929, respectively, as of June 30, 2021 and $22,682 and $1,998, respectively as of December 31, 2020. Total revenue included on the condensed consolidated statements of operations and comprehensive loss for the PCs after elimination of intercompany transactions was $17,585 and $24,719 for the three months ended June 30, 2021 and 2020, respectively. Net loss included on the condensed consolidated statements of operations and comprehensive loss was not material for the three months ended June 30, 2021 and 2020. Total revenue included on the condensed consolidated statements of operations and comprehensive loss for the PCs after elimination of intercompany transactions was $35,154 and $43,389 for the six months ended June 30, 2021 and 2020, respectively. Net loss included on the condensed consolidated statements of operations and comprehensive loss was not material for the three and six months ended June 30, 2021 and 2020.
Investment in Minority Owned Joint Venture	Investment in Minority Owned Joint Venture The Company and Cleveland Clinic partnered to form a joint venture, under the name CCAW, JV LLC, to provide broad access to comprehensive and high acuity care services via telehealth. The Company does not have a controlling financial interest in CCAW, JV LLC, but it does have the ability to exercise significant influence over the operating and financial policies of CCAW, JV LLC. Therefore, the Company accounts for its investment in CCAW, JV LLC using the equity method of accounting. The joint venture is considered a variable interest entity under ASC 810-10, but the Company is not the primary beneficiary as it does not have the power to direct the activities of the joint venture that most significantly impact its performance. The Company’s evaluation of ability to impact performance is based on Cleveland Clinic’s managing directors and Cleveland Clinic’s ability to appoint and remove the chairperson who has the ability to cast the tie breaking vote on the most significant activities. In 2020 the Company contributed $2,940 as its initial investment for a 49% interest in CCAW, JV LLC. The agreement also requires aggregate total capital contributions by the Company up to an additional $11,800 in two phases, which is yet to be defined. During the six months ended June 30, 2021, the Company made a capital contribution of $2,548, related to a portion of the phase one capital commitment. For the three months ended June 30, 2021 and 2020, the Company recognized a loss of $722 and $444 as its proportionate share of the joint venture’s results of operations, respectively. For the six months ended June 30, 2021 and 2020, the Company recognized a loss of $1,541 and $764 as its proportionate share of the joint venture’s results of operations, respectively. Accordingly, the carrying value of the equity method investment as of June 30, 2021 and December 31, 2020 was $1,759 and $752, respectively.
Concentrations of Credit Risk and Significant Customers	Concentrations of Credit Risk and Significant Customers Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, cash equivalents, investments and accounts receivable. The Company invests its excess cash with large financial institutions that the Company believes are of high credit quality. Cash and cash equivalents are invested in highly rated money market funds. At times, the Company’s cash balances with individual banking institutions are in excess of federally insured limits. The Company’s investments are invested in U.S. government agency bonds. The Company has not experienced any losses on its deposits of cash, cash equivalents or investments. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. The Company performs ongoing assessments and credit evaluations of its customers to assess the collectability of the accounts based on a number of factors, including past transaction experience, age of the accounts receivable, review of the invoicing terms of the contracts, and recent communication with customers. The Company has not experienced significant credit losses from its accounts receivable. As of June 30, 2021 and December 31, 2020, one customer accounted for 14% and 19% of outstanding accounts receivable, respectively. During the three months ended June 30, 2021 and 2020, sales to one customer (who was a related party during the 2020 period noted) represented 25% and 22% of the Company’s total revenue, respectively. During the six months ended June 30, 2021 and 2020, sales to one customer (who was a related party during the periods noted) represented 25% and 22% of the Company’s total revenue, respectively.
Emerging Growth Company Status	Emerging Growth Company Status The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with certain new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it is (i) no longer an emerging growth company or (ii) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Requirements for Fair Value Measurement In August 2018, the FASB issued ASU 2018-15, Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which simplifies the accounting for income taxes by removing certain exceptions and clarifying and amending existing guidance. ASU 2019-12 removes certain exceptions for performing intraperiod tax allocations, recognizing deferred taxes for investments, and calculating income taxes in interim periods. The guidance also simplifies the accounting for franchise taxes, transactions that result in a step-up in the tax basis of goodwill, and the effect of enacted changes in tax laws or rates in interim periods. For public entities that are Securities and Exchange Commission filers, excluding entities eligible to be smaller reporting companies, ASU 2019-12 is effective for annual periods beginning after December 15, 2020, including interim periods within those fiscal years. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2021, and interim periods within fiscal years beginning after December 15, 2022. Early adoption is permitted. The guidance was adopted effective January 1, 2021 and did not have a material impact on the condensed consolidated financial statements and disclosures.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments Codification Improvements to Topic 326, Financial Instruments—Credit Losses Financial Instruments—Credit Losses (Topic 326): Targeted Transition Relief are Securities and Exchange Commission filers, excluding entities eligible to be smaller reporting companies, ASU 2016-13 is effective for annual periods beginning after December 15, 2019, including interim periods within those fiscal years. For all other entities, ASU 2016-13 is effective for annual periods beginning after December 15, 2022, including interim periods within those fiscal years. Early adoption is permitted. Th e guidance will be adopted in the 2021 annual condensed consolidated financial statements. The Company is currently evaluating the impact that the adoption of ASU 2016-13 will have on its condensed consolidated financial statements.
Accounts Receivable, Net	Accounts Receivable, Net Accounts receivable primarily consist of amounts billed currently due from customers. Accounts receivable are presented net of an allowance for doubtful accounts, which is an estimate of amounts that may not be collectible. In determining the amount of the allowance at each reporting date, the Company makes judgments about general economic conditions, historical write-off experience and any specific risks identified in customer collection matters, including the aging of unpaid accounts receivable and changes in customer financial conditions. Account balances are written off after all means of collection are exhausted and the potential for non-recovery is determined to be probable. Adjustments to the allowance for doubtful accounts are recorded as general and administrative expenses in the condensed consolidated statements of operations and comprehensive loss.

Revenue (Tables)

Revenue (Tables)	6 Months Ended
	Jun. 30, 2021
Revenue From Contract With Customer [Abstract]
Summary of Disaggregation of Revenue	The following table presents the Company’s revenues disaggregated by revenue source: Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Platform subscription $ 26,780 $ 24,458 $ 51,376 $ 46,214 Visits 27,532 36,017 55,353 62,481 Other 5,905 8,093 11,087 13,587 Total Revenue $ 60,217 $ 68,568 $ 117,816 $ 122,282
Summary of Changes in the Allowance for Doubtful Accounts	Changes in the allowance for doubtful accounts were as follows: Six Months Ended June 30, Year Ended December 31, 2020 Allowance for doubtful accounts, beginning of the period $ 1,556 $ 686 Provisions (57 ) 1,646 Write-offs (460 ) (776 ) Allowance for doubtful accounts, end of the period $ 1,039 $ 1,556
Summary of Significant Changes in the Company's Deferred Revenue	Significant changes in the Company’s deferred revenue balance for the six months ended June 30, 2021 and the year ended December 31, 2020 were as follows: Six Months Ended June 30, Year Ended December 31, 2020 Total deferred revenue, beginning of the period $ 74,800 $ 77,386 Additions 45,487 109,542 Recognized (54,921 ) (112,128 ) Total deferred revenue, end of the period $ 65,366 $ 74,800 Current deferred revenue 57,836 66,693 Non-current deferred revenue 7,530 8,107 Total $ 65,366 $ 74,800

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2021
Fair Value Disclosures [Abstract]
Fair Value Measurements	The following tables presents the Company’s fair value hierarchy for its assets and liabilities that are measured at fair value on a recurring basis and indicate the level within the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value: June 30, 2021 Level 1 Level 2 Level 3 Total Money market funds $ 814,087 $ — $ — $ 814,087 Investments — — — $ — $ 814,087 $ — $ — $ 814,087 December 31, 2020 Level 1 Level 2 Level 3 Total Money market funds $ 892,934 $ — $ — $ 892,934 Investments — 99,963 — 99,963 $ 892,934 $ 99,963 $ — $ 992,897

Investments (Tables)

Investments (Tables)	6 Months Ended
	Jun. 30, 2021
Investments Debt And Equity Securities [Abstract]
Debt securities, available-for-sale	As of June 30, 2021 and December 31, 2020, the fair value of the Company’s investments by type of security was as follows: June 30, 2021 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Assets: U.S government securities $ — $ — $ — $ — $ — $ — $ — $ — December 31, 2020 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Assets: U.S government securities $ 99,854 $ 109 $ — $ 99,963 $ 99,854 $ 109 $ — $ 99,963

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	6 Months Ended
	Jun. 30, 2021
Goodwill And Intangible Assets Disclosure [Abstract]
Schedule of Goodwill	Goodwill consisted of the following: Six Months Ended June 30, Year Ended December 31, 2020 Beginning Balance as of January 1 $ 193,877 $ 193,877 Goodwill acquired — — Ending Balance $ 193,877 $ 193,877
Schedule of Finite-Lived Intangible Assets	Identified intangible assets consisted of the following: Gross Amount Accumulated Amortization Carrying Value Weighted Average Remaining Life June 30, 2021 Customer relationships $ 38,782 $ (13,363 ) $ 25,419 6.5 Contractor relationships 535 (226 ) $ 309 7.5 Technology 37,063 (11,119 ) $ 25,944 7.0 $ 76,380 $ (24,708 ) $ 51,672 Gross Amount Accumulated Amortization Carrying Value Weighted Average Remaining Life December 31, 2020 Customer relationships $ 38,782 $ (11,380 ) $ 27,402 7.0 Contractor relationships 535 (206 ) 329 8.0 Trade name 300 (300 ) — — Technology 37,063 (9,266 ) 27,797 7.5 $ 76,680 $ (21,152 ) $ 55,528
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense	Estimated future amortization expense of the identified intangible assets as of June 30, 2021, is as follows: 2021 $ 3,856 2022 7,712 2023 7,712 2024 7,712 2025 7,712 Thereafter 16,968 $ 51,672

Accrued Expenses and Other Cu_2

Accrued Expenses and Other Current Liabilities (Tables)	6 Months Ended
	Jun. 30, 2021
Payables And Accruals [Abstract]
Summary of Accrued Expenses and Other Current Liabilities	Accrued expenses and other current liabilities consist of the following: Six Months Ended June 30, Year Ended December 31, 2020 Employee compensation and benefits $ 10,059 $ 20,521 Professional services 3,763 6,832 Provider services 3,937 4,632 Other 7,105 10,150 Total $ 24,864 $ 42,135

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	6 Months Ended
	Jun. 30, 2021
Stockholders Equity Note [Abstract]
Convertible Preferred Stock	The authorized, issued and outstanding shares, liquidation preference, and carrying value of the Company’s convertible preferred stock as of December 31, 2019 were as follows: Shares Authorized Shares Issued Shares Outstanding Liquidation Preference Carrying Value Series A 3,200,000 3,178,650 3,130,077 51,741 28,889 Series B 833,334 787,725 787,725 37,060 23,632 Series C 13,711,111 10,095,133 10,095,133 519,648 603,278 17,744,445 14,061,508 14,012,935 608,449 655,799
Schedule of Common Stock	As of June 30, 2021, the par value of the Class A, Class B and Class C shares was $2,099, $267, and $56, respectively. Shares Authorized Shares Issued Shares Outstanding Class A 1,000,000,000 209,875,389 209,875,389 Class B 100,000,000 26,687,959 26,687,959 Class C 200,000,000 5,555,555 5,555,555 1,300,000,000 242,118,903 242,118,903
Activity under Plans	Activity under the Plans is as follows: Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Outstanding as of January 1, 2021 23,167,514 $ 4.37 6.2 $ 487,758 Granted — $ — Forfeited (317,894 ) $ 5.70 Expired — $ — Exercised (5,286,866 ) $ 3.25 Outstanding as of June 30, 2021 17,562,754 4.68 6.2 $ 140,880 Vested and expected to vest as of December 31, 2020 21,744,937 $ 4.14 6.0 $ 460,712 Vested and expected to vest as of June 30, 2021 16,685,854 $ 4.46 6.1 $ 135,479 Options exercisable as of December 31, 2020 17,640,827 $ 3.71 5.5 $ 381,511 Options exercisable as of June 30, 2021 13,809,991 $ 4.13 5.7 $ 116,756
Weighted Average of Assumptions used to Determine Fair Value of Common Stock Options Granted	The weighted-average of assumptions that the Company used to determine the fair value of the common stock options granted to employees and directors were as follows: Six Months Ended June 30, 2021 2020 Risk-free interest rate N/A 1.32 % Expected term (in years) N/A 6.1 Expected volatility N/A 51 % Expected dividend yield N/A 0 %
Summary of Unvested Restricted Stock Unit Activity	Activity for the restricted stock units is as follows: Shares Weighted Average Grant Date Fair Value Unvested as of January 1, 2021 11,014,450 $ 14.43 Granted 6,409,182 19.95 Vested (1,698,742 ) 9.56 Forfeited (108,946 ) 15.75 Unvested as of June 30, 2021 15,615,944 $ 17.22
Stock-Based Compensation Expense	Stock-based compensation expense was classified in the condensed consolidated statements of operations and comprehensive loss as follows: Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Cost of revenues $ 521 $ 168 $ 910 $ 359 Research and development 2,171 988 3,678 1,436 Selling and marketing 2,100 756 3,989 1,546 General and administrative 5,934 65,726 10,791 68,755 Total $ 10,726 $ 67,638 $ 19,368 $ 72,096

Net Loss per Share (Tables)

Net Loss per Share (Tables)	6 Months Ended
	Jun. 30, 2021
Earnings Per Share [Abstract]
Summary of Basic and Diluted Net Loss Per Share Attributable To Common Stockholders	Basic and diluted net loss per share attributable to common stockholders was calculated as follows: Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Numerator: Net loss $ (38,136 ) $ (88,220 ) $ (77,941 ) $ (113,444 ) Net loss attributable to non-controlling interest (277 ) (1,562 ) (894 ) (2,405 ) Net loss attributable to American Well Corporation $ (37,859 ) $ (86,658 ) $ (77,047 ) $ (111,039 ) Denominator: Weighted-average common shares outstanding —basic and diluted 249,366,652 43,484,313 246,471,733 41,793,108 Net loss per share attributable to common stockholders—basic and diluted $ (0.15 ) $ (1.99 ) $ (0.31 ) $ (2.66 )
Summary of Antidilutive Securities Excluded From Computation of Net Loss Per Share	The Company excluded the following potential common shares equivalents presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect: Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Convertible preferred stock (as converted to common stock) — 136,625,900 — 136,625,900 Unvested restricted stock units 7,724,006 2,028,461 7,724,006 2,028,461 Options to purchase shares of common stock 17,562,754 25,033,565 17,562,754 25,033,565 25,286,760 163,687,926 25,286,760 163,687,926

Organization and Description _2

Organization and Description of Business - Additional Information (Detail) - USD ($) $ in Thousands	Sep. 21, 2020	Jun. 30, 2021	Dec. 31, 2020
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Description of the stock split arrangement		8.8-for-1.0
Proceeds from private placement	$ 100,000
Accumulated deficit		$ 708,587	$ 582,359
Cash, cash equivalents and investments		$ 975,187
IPO [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Proceeds from issuance of common stock	$ 822,267

Summary of Significant Accoun_3

Summary of Significant Accounting Policies - Additional Information (Detail) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2021USD ($)	Jun. 30, 2020USD ($)	Jun. 30, 2021USD ($)Segment	Jun. 30, 2020USD ($)	Dec. 31, 2020USD ($)
Summary Of Significant Accounting Policies [Line Items]
Number of reportable segment | Segment			1
Number of operating segment | Segment			1
Total assets	$ 1,292,319		$ 1,292,319		$ 1,376,646
Total liabilities	99,676		99,676		$ 130,449
Payment to acquire interest in joint venture			2,548	$ 2,940
Share of the net profit loss in the operations of joint venture	$ (722)	$ (444)	$ (1,541)	$ (764)
Accounting Standards Update 2018-13 [Member]
Summary Of Significant Accounting Policies [Line Items]
Change in accounting principle, accounting standards update, adopted [true false]	true		true
Change in accounting principle, accounting standards update, adoption date	Jan. 1, 2020		Jan. 1, 2020
Change in accounting principle, accounting standards update, immaterial effect [true false]	true		true
Accounting Standards Update 2018-15 [Member]
Summary Of Significant Accounting Policies [Line Items]
Change in accounting principle, accounting standards update, adopted [true false]	true		true
Change in accounting principle, accounting standards update, adoption date	Jan. 1, 2020		Jan. 1, 2020
Change in accounting principle, accounting standards update, immaterial effect [true false]	true		true
Accounting Standards Update 2019-12 [Member]
Summary Of Significant Accounting Policies [Line Items]
Change in accounting principle, accounting standards update, adopted [true false]	true		true
Change in accounting principle, accounting standards update, adoption date	Jan. 1, 2021		Jan. 1, 2021
Change in accounting principle, accounting standards update, immaterial effect [true false]	true		true
Customer Concentration Risk | Accounts Receivable [Member]
Summary Of Significant Accounting Policies [Line Items]
Percentage of net total revenue			14.00%		19.00%
Customer Concentration Risk | Revenue Benchmark [Member]
Summary Of Significant Accounting Policies [Line Items]
Percentage of net total revenue	25.00%	22.00%	25.00%	22.00%
Variable Interest Entity, Primary Beneficiary [Member]
Summary Of Significant Accounting Policies [Line Items]
Total assets	$ 30,207		$ 30,207		$ 22,682
Total liabilities	1,929		1,929		1,998
Total revenue	17,585	$ 24,719	35,154	$ 43,389
Variable Interest Entity, Primary Beneficiary [Member] | CCACV JV LLC [Member]
Summary Of Significant Accounting Policies [Line Items]
Payment to acquire interest in joint venture					$ 2,940
Percentage of ownership interest in joint venture					49.00%
Estimated additional total capital contributions necessary					$ 11,800
Additional capital contribution related to portion of phase one capital commitment			2,548
Share of the net profit loss in the operations of joint venture	722	$ 444	1,541	$ 764
Equity method investment carrying value	$ 1,759		$ 1,759		$ 752
Maximum [Member]
Summary Of Significant Accounting Policies [Line Items]
Percentage of economic or ownership interest in consolidated entities			100.00%

Revenue - Summary of Disaggrega

Revenue - Summary of Disaggregation of Revenue (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Disaggregation of Revenue [Line Items]
Total Revenue	$ 60,217	$ 68,568	$ 117,816	$ 122,282
Platform Subscription [Member]
Disaggregation of Revenue [Line Items]
Total Revenue	26,780	24,458	51,376	46,214
Visits [Member]
Disaggregation of Revenue [Line Items]
Total Revenue	27,532	36,017	55,353	62,481
Others [Member]
Disaggregation of Revenue [Line Items]
Total Revenue	$ 5,905	$ 8,093	$ 11,087	$ 13,587

Revenue - Summary of Changes in

Revenue - Summary of Changes in the Allowance for Doubtful Accounts (Detail) - USD ($) $ in Thousands	6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Revenue From Contract With Customer [Abstract]
Allowance for doubtful accounts, beginning of the period	$ 1,556	$ 686	$ 686
Provisions	(57)	$ 640	1,646
Write-offs	(460)		(776)
Allowance for doubtful accounts, end of the period	$ 1,039		$ 1,556

Revenue - Additional Informatio

Revenue - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Revenue From Contract With Customer Line Items [Line Items]
Contract liability revenue recognized	$ 21,238	$ 18,985	$ 39,146	$ 41,731
Transaction price allocated to remaining performance obligations	$ 190,413		$ 190,413		$ 192,238
Performance obligation percentage of transaction price to recognized in the next twelve months	47.00%		47.00%
Unbilled Revenues [Member]
Revenue From Contract With Customer Line Items [Line Items]
Unbilled accounts receivable	$ 3,387		$ 3,387		$ 3,376

Revenue - Summary of Contract w

Revenue - Summary of Contract with Customer Asset and Liability (Detail) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Revenue From Contract With Customer [Abstract]
Total deferred revenue, beginning of the period	$ 74,800	$ 77,386
Additions	45,487	109,542
Recognized	(54,921)	(112,128)
Total deferred revenue, end of the period	$ 65,366	$ 74,800

Revenue - Summary of Contract_2

Revenue - Summary of Contract with Customer Liability Current and Non Current (Detail) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Revenue From Contract With Customer [Abstract]
Current deferred revenue	$ 57,836	$ 66,693
Non-current deferred revenue	7,530	8,107
Total	$ 65,366	$ 74,800	$ 77,386

Revenue - Additional Informat_2

Revenue - Additional Information (Detail1)	Jun. 30, 2021	Dec. 31, 2020
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2021-01-01
Revenue From Contract With Customer Line Items [Line Items]
Revenue remaining performance obligation expected timing of satisfaction		3 years
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2021-07-01
Revenue From Contract With Customer Line Items [Line Items]
Revenue remaining performance obligation expected timing of satisfaction	3 years

National Telehealth Network - A

National Telehealth Network - Additional Information (Detail) - NTN [Member] - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020	Jan. 01, 2016
Schedule of Equity Method Investments [Line Items]
Loss from equity method investments	$ 277	$ 1,562	$ 894	$ 2,405
Noncontrolling Interest [Member]
Schedule of Equity Method Investments [Line Items]
Non controlling interest carrying value	$ 21,171		$ 21,171		$ 22,065
Minimum [Member]
Schedule of Equity Method Investments [Line Items]
Business combination step acquisition equity interest in acquiree including subsequent acquisition percentage						50.00%
Maximum [Member]
Schedule of Equity Method Investments [Line Items]
Business combination step acquisition equity interest in acquiree including subsequent acquisition percentage						100.00%

Fair Value Measurements - Fair

Fair Value Measurements - Fair Value of Assets and Liabilities Measured on Recurring Basis (Detail) - Fair Value, Recurring [Member] - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets, Fair Value Disclosure	$ 814,087	$ 992,897
Money Market Funds [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets, Fair Value Disclosure	814,087	892,934
Investments [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets, Fair Value Disclosure		99,963
Fair Value, Inputs, Level 1 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets, Fair Value Disclosure	814,087	892,934
Fair Value, Inputs, Level 1 [Member] | Money Market Funds [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets, Fair Value Disclosure	$ 814,087	892,934
Fair Value, Inputs, Level 2 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets, Fair Value Disclosure		99,963
Fair Value, Inputs, Level 2 [Member] | Investments [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets, Fair Value Disclosure		$ 99,963

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Detail)	6 Months Ended
	Jun. 30, 2021USD ($)
Fair Value Disclosures [Abstract]
Transfer from level one to level two fair value assets	$ 0
Transfer from level one to level three fair value assets	0
Transfer from level two to level one fair value assets	0
Transfer from level three to level one fair value assets	$ 0

Investments - Debt Securities,

Investments - Debt Securities, Available-For-Sale (Detail) $ in Thousands	Dec. 31, 2020USD ($)
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	$ 99,854
Gross Unrealized Gains	109
Fair Value	99,963
U.S government securities [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	99,854
Gross Unrealized Gains	109
Fair Value	$ 99,963

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets - Schedule of Goodwill (Detail) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Goodwill And Intangible Assets Disclosure [Abstract]
Beginning Balance as of January 1	$ 193,877	$ 193,877
Ending Balance	$ 193,877	$ 193,877

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets - Schedule of finite lived Intangible Assets (Detail) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Finite Lived Intangible Assets [Line Items]
Gross Amount	$ 76,380	$ 76,680
Accumulated Amortization	(24,708)	(21,152)
Carrying Value	51,672	55,528
Customer relationships [Member]
Finite Lived Intangible Assets [Line Items]
Gross Amount	38,782	38,782
Accumulated Amortization	(13,363)	(11,380)
Carrying Value	$ 25,419	$ 27,402
Weighted Average Remaining Life	6 years 6 months	7 years
Contractor relationships [Member]
Finite Lived Intangible Assets [Line Items]
Gross Amount	$ 535	$ 535
Accumulated Amortization	(226)	(206)
Carrying Value	$ 309	$ 329
Weighted Average Remaining Life	7 years 6 months	8 years
Technology [Member]
Finite Lived Intangible Assets [Line Items]
Gross Amount	$ 37,063	$ 37,063
Accumulated Amortization	(11,119)	(9,266)
Carrying Value	$ 25,944	$ 27,797
Weighted Average Remaining Life	7 years	7 years 6 months
Trade name [Member]
Finite Lived Intangible Assets [Line Items]
Gross Amount		$ 300
Accumulated Amortization		$ (300)
Weighted Average Remaining Life		0 years

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Goodwill And Intangible Assets Disclosure [Abstract]
Amortization of intangible assets	$ 1,928	$ 1,938	$ 3,856	$ 3,877

Goodwill and Intangible Asset_5

Goodwill and Intangible Assets - Schedule of Finite Lived Intangible Assets Future Amortization Expense (Detail) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Goodwill And Intangible Assets Disclosure [Abstract]
2021	$ 3,856
2022	7,712
2023	7,712
2024	7,712
2025	7,712
Thereafter	16,968
Carrying Value	$ 51,672	$ 55,528

Accrued Expenses and Other Cu_3

Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Detail) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Payables And Accruals [Abstract]
Employee compensation and benefits	$ 10,059	$ 20,521
Professional services	3,763	6,832
Provider services	3,937	4,632
Other	7,105	10,150
Total	$ 24,864	$ 42,135

Line of Credit - Additional Inf

Line of Credit - Additional Information (Detail) - USD ($)	Jan. 31, 2011	Jun. 30, 2021	Dec. 31, 2020	Nov. 30, 2017
Line of Credit Facility [Line Items]
Letter of credit outstanding		$ 795,000	$ 1,095,000
Two Thousand and Eleven Line of Credit Facility [Member]
Line of Credit Facility [Line Items]
Line of credit maximum borrowing capacity	$ 5,000,000
Two Thousand and Eleven Line of Credit Facility [Member] | London Interbank Offered Rate (LIBOR) [Member]
Line of Credit Facility [Line Items]
Debt instrument variable interest rate spread	1.25%
Two Thousand and Seventeen Amended Line of Credit Facility [Member]
Line of Credit Facility [Line Items]
Line of credit maximum borrowing capacity				$ 7,000,000
Line of credit net of current portion outstanding		0	0
Line of credit remaining borrowing capacity		$ 6,205,000	$ 5,905,000

Stockholders' Equity - Converti

Stockholders' Equity - Convertible Preferred Stock (Detail) $ in Thousands	Dec. 31, 2019USD ($)shares
Redeemable Noncontrolling Interest [Line Items]
Shares Authorized	17,744,445
Shares Issued	14,061,508
Shares Outstanding	14,012,935
Liquidation Preference | $	$ 608,449
Carrying Value | $	$ 655,799
Series A [Member]
Redeemable Noncontrolling Interest [Line Items]
Shares Authorized	3,200,000
Shares Issued	3,178,650
Shares Outstanding	3,130,077
Liquidation Preference | $	$ 51,741
Carrying Value | $	$ 28,889
Series B [Member]
Redeemable Noncontrolling Interest [Line Items]
Shares Authorized	833,334
Shares Issued	787,725
Shares Outstanding	787,725
Liquidation Preference | $	$ 37,060
Carrying Value | $	$ 23,632
Series C [Member]
Redeemable Noncontrolling Interest [Line Items]
Shares Authorized	13,711,111
Shares Issued	10,095,133
Shares Outstanding	10,095,133
Liquidation Preference | $	$ 519,648
Carrying Value | $	$ 603,278

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail)	1 Months Ended			3 Months Ended		6 Months Ended		12 Months Ended
	Sep. 30, 2020USD ($)$ / sharesshares	May 31, 2020USD ($)$ / sharesshares	Feb. 29, 2020USD ($)$ / sharesshares	Jun. 30, 2021USD ($)$ / sharesshares	Jun. 30, 2020USD ($)	Jun. 30, 2021USD ($)$ / sharesshares	Jun. 30, 2020USD ($)$ / sharesshares	Dec. 31, 2020$ / sharesshares	Aug. 31, 2020shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Preferred stock authorized				100,000,000		100,000,000		100,000,000
Preferred stock per share | $ / shares	$ 0.01			$ 0.01		$ 0.01		$ 0.01
Common stock authorized				1,300,000,000		1,300,000,000
Common stock reserve for issuance				66,187,346		66,187,346		61,392,747
Expected volatility							51.00%
Stock-based compensation expenses | $				$ 10,726,000	$ 67,638,000	$ 19,368,000	$ 72,096,000
Restricted Stock [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Restricted stock units							2,616,345	13,816,885
Fair value of RSU’s granted | $						127,834,000
Aggregate intrinsic value of restricted stock units vested | $						$ 35,223,000	$ 1,693,000
Restricted Stock [Member] | Minimum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Award Requisite Service Period						1 year		1 year
Restricted Stock [Member] | Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Award Requisite Service Period						4 years		4 years
2020 Equity Incentive Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options, granted						0
Weighted-average grant date fair value of common stock | $ / shares							$ 3.88
Executive Equity Awards [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected stock based compensation | $						$ 23,644,000
Executive Equity Awards [Member] | Chief Executive Officer [Member] | Restricted Stock [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of restricted stock units issued						3,230,750
Share based payment award percentage of outstanding stock						1.50%
Share price | $ / shares				$ 9.96		$ 9.96
Expected volatility						60.00%
Executive Equity Awards [Member] | Chief Executive Officer [Member] | Share-based Payment Arrangement, Tranche One [Member] | Restricted Stock [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of fully-diluted outstanding capital stock	50.00%					50.00%
Executive Equity Awards [Member] | Chief Executive Officer [Member] | Share-based Payment Arrangement, Tranche Two [Member] | Restricted Stock [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share based payment award percentage of outstanding stock	0.75%					0.75%
2020 Employee Stock Purchase Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserve for issuance				3,084,218		3,084,218			3,084,218
Share-based compensation arrangement by share-based payment award, discount from market price, purchase date						85.00%
Shares, issued under ESPP						0
Stock-based compensation expenses | $				$ 281,000	$ 0	$ 384,000	$ 0
Equity Award Plan [Member] | Common Stock [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized stock-based compensation | $				$ 88,396,000		$ 88,396,000
Weighted-average period						3 years
IPO [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares withheld related to net share settlement | $	$ 24,157,000
Series C Preferred Stock [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of new stock issued		1,342,750	170,000
Shares issued, price per share | $ / shares		$ 100	$ 75
Proceeds from stock issuance | $		$ 134,275,000	$ 12,750,000
Issuance cost | $		$ 750,000	$ 261,000
Convertible Preferred Stock [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Convertible preferred stock outstanding	15,525,685
Value of convertible preferred stock | $	$ 801,813,000
Preferred stock conversion basis						8.8-to-1.0
Convertible preferred stock to common stock, conversion ratio	0.113
Preferred Stock [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Preferred stock authorized	100,000,000
Common Class A [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of new stock issued	45,681,499
Common stock per share | $ / shares	$ 18
Deferred offering cost | $	$ 4,906,000
Shares of common stock pursuant to the exercise of options	4,459,277
Net proceeds from IPO | $	$ 767,568,000
Underwriting discounts and commissions | $	$ 49,336,000
Common stock authorized	1,000,000,000			1,000,000,000		1,000,000,000		1,000,000,000
Common stock per share | $ / shares	$ 0.01			$ 0.01		$ 0.01		$ 0.01
Common stock, voting rights						one
Common stock per share | $ / shares				$ 2,099		$ 2,099
Common Class C [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of new stock issued	5,555,555
Issuance of common stock in connection with Google Private Placement, net of issuance costs of $900 | $	$ 99,100,000
Purchase and issuance costs | $	$ 900,000
Common stock authorized	200,000,000			200,000,000		200,000,000		200,000,000
Common stock per share | $ / shares	$ 0.01			$ 0.01		$ 0.01		$ 0.01
Common stock, voting rights						one
Common stock per share | $ / shares				$ 56		$ 56
Common Stock Class A And Class B [Member] | IPO [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share based Payment Arrangement Shares Withheld for Tax Withholding Obligations	1,340,354
Common Class B [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock authorized	100,000,000			100,000,000		100,000,000		100,000,000
Common stock per share | $ / shares	$ 0.01			$ 0.01		$ 0.01		$ 0.01
Common stock, voting rights						(x) 1.0408163 and (y) the total number of votes that would be cast at such time by the holders of the Class A and Class C common stock and any other preferred stock entitled to vote under the certificate of incorporation at such time (resulting in the Class B common stock collectively holding 51% of the total outstanding voting power)
Number of shares converted						3,351,035
Common stock per share | $ / shares				$ 267		$ 267

Stockholders' Equity - Schedule

Stockholders' Equity - Schedule of Common Stock (Detail) - shares	Jun. 30, 2021	Dec. 31, 2020	Sep. 30, 2020
Class of Stock [Line Items]
Shares Authorized	1,300,000,000
Shares Issued	242,118,903
Shares Outstanding	242,118,903
Class A [Member]
Class of Stock [Line Items]
Shares Authorized	1,000,000,000	1,000,000,000	1,000,000,000
Shares Issued	209,875,389	201,488,097
Shares Outstanding	209,875,389	200,751,168
Class B [Member]
Class of Stock [Line Items]
Shares Authorized	100,000,000	100,000,000	100,000,000
Shares Issued	26,687,959	30,427,128
Shares Outstanding	26,687,959	29,297,382
Class C [Member]
Class of Stock [Line Items]
Shares Authorized	200,000,000	200,000,000	200,000,000
Shares Issued	5,555,555	5,555,555
Shares Outstanding	5,555,555	5,555,555

Stockholders' Equity - Activity

Stockholders' Equity - Activity under Plans (Detail) - 2020 Equity Incentive Plan [Member] $ / shares in Units, $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2021USD ($)$ / sharesshares	Dec. 31, 2020USD ($)$ / sharesshares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Shares, Outstanding, beginning of period	23,167,514
Number of Shares, Granted	0
Number of Shares, Forfeited	(317,894)
Number of Shares, Exercised	(5,286,866)
Number of Shares, Outstanding, end of period	17,562,754	23,167,514
Number of Shares, Vested and expected to vest	16,685,854	21,744,937
Number of Shares, Options exercisable	13,809,991	17,640,827
Number of Shares, Outstanding, Weighted Average Exercise Price, beginning of period | $ / shares	$ 4.37
Number of Shares, Forfeited, Weighted Average Exercise Price | $ / shares	5.70
Number of Shares, Exercised, Weighted Average Exercise Price | $ / shares	3.25
Number of Shares, Outstanding, Weighted Average Exercise Price, end of period | $ / shares	4.68	$ 4.37
Number of Shares,Vested and expected to vest, Weighted Average Exercise Price, end of period | $ / shares	4.46	4.14
Number of Shares, Options exercisable, Weighted Average Exercise Price, end of period | $ / shares	$ 4.13	$ 3.71
Number of Shares, Outstanding, Weighted Average Remaining Contractual Term (years)	6 years 2 months 12 days	6 years 2 months 12 days
Number of Shares, Vested and expected to vest, Weighted Average Remaining Contractual Term (years)	6 years 1 month 6 days	6 years
Number of Shares, Options exercisable, Weighted Average Remaining Contractual Term (years)	5 years 8 months 12 days	5 years 6 months
Number of Shares, Outstanding, Aggregate Intrinsic Value | $	$ 140,880	$ 487,758
Number of Shares, Vested and expected to vest, Aggregate Intrinsic Value | $	135,479	460,712
Number of Shares, Options exercisable, Aggregate Intrinsic Value | $	$ 116,756	$ 381,511

Stockholders' Equity - Weighted

Stockholders' Equity - Weighted Average of Assumptions used to Determine Fair Value of Common Stock Options Granted (Detail)	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Stockholders Equity Note [Abstract]
Risk-free interest rate		1.32%
Expected term (in years)	0 years	6 years 1 month 6 days
Expected volatility		51.00%
Expected dividend yield		0.00%

Stockholders' Equity - Summary

Stockholders' Equity - Summary of Unvested Restricted Stock Unit Activity (Detail) - Restricted Stock Units [Member]	6 Months Ended
	Jun. 30, 2021$ / sharesshares
Class of Stock [Line Items]
Shares, Unvested as of January 1, 2021 | shares	11,014,450
Shares, Granted | shares	6,409,182
Shares, Vested | shares	(1,698,742)
Shares, Forfeited | shares	(108,946)
Shares, Unvested as of June 30, 2021 | shares	15,615,944
Shares, Unvested, Weighted Average Grant Date Fair Value, as of January 1, 2020 | $ / shares	$ 14.43
Shares, Unvested, Granted, Weighted Average Grant Date Fair Value | $ / shares	19.95
Shares, Unvested, Vested, Weighted Average Grant Date Fair Value | $ / shares	9.56
Shares, Unvested, Forfeited, Weighted Average Grant Date Fair Value | $ / shares	15.75
Shares, Unvested as of December 31, 2020 | $ / shares	$ 17.22

Stockholders' Equity - Stock-Ba

Stockholders' Equity - Stock-Based Compensation Expense (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expenses	$ 10,726	$ 67,638	$ 19,368	$ 72,096
Cost of revenues [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expenses	521	168	910	359
Research and development [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expenses	2,171	988	3,678	1,436
Selling and marketing [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expenses	2,100	756	3,989	1,546
General and administrative [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expenses	$ 5,934	$ 65,726	$ 10,791	$ 68,755

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail)	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Pending Litigation [Member]
Loss Contingencies [Line Items]
Pending Claims Number	0	0
Indemnification Agreement [Member]
Loss Contingencies [Line Items]
New Claims Filed, Number	0	0

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Income Tax Disclosure [Abstract]
Income tax expense	$ 103	$ 252	$ 412	$ 252

Related-Party Transactions - Ad

Related-Party Transactions - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Related Party Transaction [Line Items]
Deferred revenue	$ 65,366		$ 65,366		$ 74,800	$ 77,386
Revenues recognized from related party			(54,921)		(112,128)
Payment to acquire interest in joint venture			2,548	$ 2,940
Payment to executive officers for stock tax loans					16,441
CCAW JV LLC [Member]
Related Party Transaction [Line Items]
Deferred revenue	840		840		1,496
Due from related parties	0		0		0
Revenues recognized from related party	412	$ 393	874	786
Payment to acquire interest in joint venture			2,548		$ 2,940
Equity method investment, ownership percentage					50.00%
Teva Pharmaceuticals Industries Ltd [Member]
Related Party Transaction [Line Items]
Deferred revenue	0		0		$ 0
Due from related parties	0		0		0
Revenues recognized from related party	0	0	0	0
Philips Holding USA Inc [Member]
Related Party Transaction [Line Items]
Deferred revenue	977		977		2,549
Due from related parties	547		547		763
Revenues recognized from related party	758	368	1,658	708
Anthem Inc [Member]
Related Party Transaction [Line Items]
Deferred revenue					11,347
Due from related parties					8,391
Revenues recognized from related party		14,848	7,218	27,155
Cleveland Clinic [Member]
Related Party Transaction [Line Items]
Deferred revenue	451		451		606
Due from related parties	85		85		$ 1,020
Revenues recognized from related party	$ 279	$ 294	$ 530	$ 490

Net Loss per Share - Schedule o

Net Loss per Share - Schedule of Earnings Per Share (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2021	Jun. 30, 2020
Numerator:
Net loss	$ (38,136)	$ (39,805)	$ (88,220)	$ (25,224)	$ (77,941)	$ (113,444)
Net loss attributable to non-controlling interest	(277)		(1,562)		(894)	(2,405)
Net loss attributable to American Well Corporation	$ (37,859)		$ (86,658)		$ (77,047)	$ (111,039)
Denominator:
Weighted-average common shares outstanding, basic and diluted	249,366,652		43,484,313		246,471,733	41,793,108
Net loss per share attributable to common stockholders, basic and diluted	$ (0.15)		$ (1.99)		$ (0.31)	$ (2.66)

Net Loss per Share - Schedule_2

Net Loss per Share - Schedule of Antidilutive Securities Excluded From Computation of Earning Per Share (Detail) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	25,286,760	163,687,926	25,286,760	163,687,926
Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount		136,625,900		136,625,900
Unvested restricted stock units [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	7,724,006	2,028,461	7,724,006	2,028,461
Options to purchase shares of common stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	17,562,754	25,033,565	17,562,754	25,033,565

Subsequent Events- Additional I

Subsequent Events- Additional Information (Detail) $ in Thousands	Jul. 28, 2021USD ($)shares	Jul. 28, 2021Agreement	Jul. 27, 2021USD ($)shares	Jul. 19, 2021USD ($)	Jun. 30, 2021
Employment Agreement | Brendan O' Grady [Member] | Common Stock [Member] | Restricted Stock Units [Member]
Subsequent Event [Line Items]
Vesting description					with 25% of the restricted stock units being vested on the grant date, and the remaining vesting ratably every 3 months thereafter over a four-year period (beginning on the first calendar day of the month following the date that is three months following the grant date)
Subsequent Event [Member]
Subsequent Event [Line Items]
Number of purchase agreements to acquire business | Agreement		2
Subsequent Event [Member] | Employment Agreement | Brendan O' Grady [Member]
Subsequent Event [Line Items]
Annual base salary				$ 485
Percentage of annual target bonus out of annual base salary				200.00%
Subsequent Event [Member] | Employment Agreement | Brendan O' Grady [Member] | Restricted Stock Units [Member]
Subsequent Event [Line Items]
Percentage of fully-diluted outstanding capital stock				25.00%
Restricted stock units vesting period				4 years
Subsequent Event [Member] | Employment Agreement | Brendan O' Grady [Member] | Common Class A [Member] | Common Stock [Member] | Restricted Stock Units [Member]
Subsequent Event [Line Items]
Grant date value of restricted stock units				$ 8,000
Subsequent Event [Member] | Conversa Health Inc. [Member]
Subsequent Event [Line Items]
Aggregate purchase price			$ 110,000
Aggregate purchase price, cash			55,000
Aggregate purchase price, stock value			$ 55,000
Aggregate purchase price, shares | shares			4,700,000
Increase in consideration transferred, subject to financial performance			$ 30,000
Effective date of acquisition			Aug. 10, 2021
Subsequent Event [Member] | Silver Cloud Health Holdings, Inc. [Member]
Subsequent Event [Line Items]
Aggregate purchase price	$ 210,000
Aggregate purchase price, cash	110,000
Aggregate purchase price, stock value	$ 100,000
Aggregate purchase price, shares | shares	8,500,000
Increase in consideration transferred, subject to financial performance	$ 40,000